Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06615752 | RECRUITING | Metastatic Castration-resistant Prostate Cancer (mCRPC)

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Sponsor:

Charles Drew University of Medicine and Science

Information provided by (Responsible Party):

Ask Wang

Brief Summary:

The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination. Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.

Condition or disease

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Intervention/treatment

green tea and quercetin + docetaxel

Placebo + docetaxel

Phase

PHASE1

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 99 participants
Masking : QUADRUPLE
Primary Purpose : TREATMENT
Official Title : A Phase I/II Study to Determine the Safety and Efficacy of a Combination of Green Tea and Quercetin With Docetaxel in Castration-resistant Prostate Cancer Patients
Actual Study Start Date : 2026-03
Estimated Primary Completion Date : 2028-04
Estimated Study Completion Date : 2029-02

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization.
  • * Stated willingness to comply with all study procedures and availability for the duration of the study.
  • * Male patients 18 years or older
  • * Diagnosed with metastatic prostate cancer
  • * History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
  • * Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
  • * Clinical decision to start doc infusion with prednisone treatment
  • * Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³)
  • * Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN)
  • * Adequate renal function (serum creatinine level within normal limits)
  • * At least a 6-month or greater life expectancy
  • * Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention
Exclusion Criteria
  • * Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
  • * Any comorbid condition that would preclude the administration of docetaxel/prednisone
  • * Ongoing alcohol abuse
  • * Significant medical or psychiatric conditions that would make the patient a poor protocol candidate
  • * Prior allergic reaction to tea, tea products or quercetin supplements
  • * Allergies to multiple food items or nutritional supplements
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Location Details

NCT06615752

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

Charles R. Drew University of Medicine and Science

Los Angeles, California, United States, 90059